PLAU and neoplasm: In vivo studies showed that uPA-sEVs-siSrc alone can reduce tumor size, and combined treatment of uPA-sEVs-siSrc with the senescence-inducing chemotherapy DOX can significantly reduce senescence burden and halt tumor progression in a tumor xenograft model of human breast cancer.